Gastrointestinal pancreatic neuroendocrine tumors
Conditions
Interventions
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Males or females aged 18-75 have a life cycle of more than 3 months; (2) Liver metastasis of gastrointestinal pancreatic neuroendocrine tumors diagnosed according to the Chinese Pathological Diagnostic Standards for Tumors (2017 edition); (3) There is at least one lesion that can be measured: 3 cm 80g/L; Platelet count (PLT) > 60*10^9/L; Leukocyte count (WBC) > 2*10^9/L; Serum albumin (Alb) > 30g/L; Alpha-alanine aminotransferase (ALT) = 3 *ULN; Glutamic-oxaloacetic transaminase (AST) = 3*ULN; Total bilirubin (TBil) = 3 *ULN; Serum creatinine (Cr) = 1.5 *ULN; (8) Female patients are not pregnant, do not breast-feed, apply effective contraceptive measures, agree not to be pregnant within the trial cycle and 12 months thereafter, and male patients agree that their spouses are not pregnant during the trial period and 12 months thereafter; (9) Voluntary treatment and informed consent.
Exclusion criteria
Exclusion criteria: (1) During the experiment, the combination of drugs may affect the evaluation of the observed indicators; (2) Leukocyte < 2.0 *109/L, platelet < 60 *10^9/L; (3) The proportion of tumors in the whole liver is more than 70%; (4) Patients with extensive extrahepatic metastasis of tumors; (5) patients with arteriovenous shunt in tumors; (6) Enhanced CT/MRI showed portal vein trunk, primary branch tumor thrombus or arteriovenous fistula; (7) Patients with severe primary diseases such as cardio-cerebrovascular disease, liver, kidney, hematopoietic system and psychosis; (8) Coagulation dysfunction that cannot be corrected; (9) Patients allergic to iodine products and related accessories; (10) Those who fail to use drugs according to the prescriptions with informed consent can not judge the curative effect, or whose data are incomplete affect the judgment of curative effect; (11) HIV infection or AIDS-related diseases; (12) In the first six months of this study, it was in the treatment stage of other clinical studies; (13) Other medical and psychological conditions that prevent patients from participating in research or signing informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective remission rate;Liver function reserve;adverse event; | — |
Countries
China
Contacts
Public ContactJingyu Liu
Shanghai Changhai Hospital
Outcome results
None listed